American CryoStem Announces Dr. Sanjay Batra as Chairman of the Medical & Scientific Advisory Board
EATONTOWN, N.J., February 28, 2013 (GLOBE NEWSWIRE) — American CryoStem Corporation (CRYO), a leading biotech company in the field of Regenerative Medicine, is pleased to announce today that Sanjay Batra, PhD, FACC has been appointed as Chairman of the Medical & Scientific Advisory Board.
Dr. Batra brings 20 years of global healthcare and entrepreneurial experience in biotech and large pharma. Dr. Batra was Vice President, R&D Pharmaceuticals, Asia-Pacific & Japan at Johnson & Johnson. Most recently Dr. Batra served as President and CEO of Aesthetic Factors, LLC, an emerging company providing autologous, point-of-care therapies in Regenerative Medicine. In this role, Dr. Batra led the commercial growth of their platelet-rich plasma and autologous fat products and was instrumental in establishing the company as the science driven leader.
“It is a pleasure to have someone of Dr. Batra’s experience lead our Medical & Scientific Advisory Board as we advance our “best-in-class” tissue based products and services. Dr. Batra is highly accomplished and respected within the medical community and will no doubt make contributions while guiding our company across all segments of the Regenerative Medicine Industry.” said John Arnone, Chairman of American CryoStem.
Dr. Batra stated, “I am very impressed with the technology platform and commercial applications pioneered by American CryoStem. The company has built a world-class team focused on the scientific advancement and commercialization of their technologies. I look forward to being part of an organization participating in one of the most rapidly emerging global markets in the health industry.”
About American CryoStem: American CryoStem Corporation (OTCQB: CRYO) is a leading biotech company focused on marketing its clinical processing services and patented products for adipose (fat) tissue and adipose derived adult stem cells. Our clinical tissue processing, patented cell culture media products and tissue storage platform supports cosmetic and regenerative medicine applications being developed globally. The Company provides high quality, clinically processed viable cells, while at the same time developing cutting edge applications, therapies, patented laboratory products and services for consumer and commercial applications.
Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “forecasts”, “may”, “should”, variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product development, product potential or financial performance. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect the business of American CryoStem Corp. and its markets, particularly those discussed in the risk factors and cautionary statements in filings made by the Company with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and the Company assumes any responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
American CryoStem Corporation